Recentin cediranib: Phase III data

AstraZeneca said it will not pursue further development of Recentin to treat recurrent glioblastoma based on top-line data from the double-blind, international Phase III REGAL trial in about 300 patients. The compound with or without lomustine chemotherapy missed the primary endpoint of significantly improving PFS vs. lomustine chemotherapy alone. Additionally, there was no benefit in OS for either Recentin group compared to chemotherapy alone. ...